Parathyroid Disorders. Группа авторов

Чтение книги онлайн.

СКАЧАТЬ target="_blank" rel="nofollow" href="#ulink_ce13b144-5961-5973-b9de-427681e2534a">43Diri H, Unluhizarci K, Kelestimur F: Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up. Endocrine 2014;47:971–972.

44Hirsch D, Kopel V, Nadler V, Levy S, Toledano Y, Tsvetov G: Pregnancy outcomes in women with primary hyperparathyroidism. J Clin Endocrinol Metab 2015;100:2115–2122.

45Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA, Lee JA, Kuo JH: Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 2017;161:70–77.

46Campennì A, Ruggeri RM, SIndoni A, Giovinazzo S, Calbo E, Ieni A, Calbo L, Tuccari G, Baldari S, Benvenga S: Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab 2012;30:367–372.

47Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L: Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013;98:87–96.

48Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, Borderie D, Kahan A, Cormier C: Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98:3213–3220.

49Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A, Cormier C: Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 2014;25:1963–1968.

50Wade TJ, Yen TW, Amin AL, Wang TS: Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 2012;36:761–766.

51Marcocci C, Bollerslev J, Khan AA, Shoback DM: Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607–3618.

52Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A: Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–1302.

53Konrade I, Dambrova G, Dambrova M: Denosumab-induced hypophosphataemia in a case of normocalcaemic primary hyperparathyroidism. Intern Med J 2017;47:974–975.

      Prof. Sabrina Corbetta

      Endocrinology and Diabetology Service and Laboratory of Experimental Endocrinology

      Department of Biomedical Sciences for Health, University of Milan

      IRCCS Istituto Ortopedico Galeazzi

      Via R. Galeazzi 4 , IT–20161 Milan (Italy)

      E-Mail [email protected]

      Конец ознакомительного фрагмента.

      Текст предоставлен ООО «ЛитРес».

      Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.

      Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.

/9j/4RpmRXhpZgAATU0AKgAAAAgABwESAAMAAAABAAEAAAEaAAUAAAABAAAAYgEbAAUAAAABAAAA agEoAAMAAAABAAIAAAExAAIAAAAiAAAAcgEyAAIAAAAUAAAAlIdpAAQAAAABAAAAqAAAANQALcbA AAAnEAAtxsAAACcQQWRvYmUgUGhvdG9zaG9wIENDIDIwMTkgKFdpbmRvd3MpADIwMTg6MTA6MzEg MTM6NDI6NDgAAAOgAQADAAAAAf//AACgAgAEAAAAAQAABkCgAwAEAAAAAQAACFgAAAAAAAAABgED AAMAAAABAAYAAAEaAAUAAAABAAABIgEbAAUAAAABAAABKgEoAAMAAAABAAIAAAIBAAQAAAABAAAB MgICAAQAAAABAAAZLAAAAAAAAABIAAAAAQAAAEgAAAAB/9j/7QAMQWRvYmVfQ00AAf/uAA5BZG9i ZQBkgAAAAAH/2wCEAAwICAgJCAwJCQwRCwoLERUPDAwPFRgTExUTExgRDAwMDAwMEQwMDAwMDAwM DAwMDAwMDAwMDAwMDAwMDAwMDAwBDQsLDQ4NEA4OEBQODg4UFA4ODg4UEQwMDAwMEREMDAwMDAwR DAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDP/AABEIAKAAeAMBIgACEQEDEQH/3QAEAAj/xAE/ AAABBQEBAQEBAQAAAAAAAAADAAECBAUGBwgJCgsBAAEFAQEBAQEBAAAAAAAAAAEAAgMEBQYHCAkK CxAAAQQBAwIEAgUHB

СКАЧАТЬ